An open-label study to assess the anti-tumor activity of Avastin [bevacizumab] in combination with fotemustine as first-line therapy in patients with metastatic melanoma.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Bevacizumab (Primary) ; Fotemustine
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Roche
- 15 Oct 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Feb 2010 Planned end date (1 Nov 2009) added as reported by ClinicalTrials.gov.